X4 Pharmaceuticals, Inc.

Equities

XFOR

US98420X1037

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 07/06/2024 BST			5-day change	1st Jan Change
1.01 ^USD	-0.98%		0.00%	+20.45%

05-09	Sector Update: Health Care Stocks Higher Late Afternoon	MT
05-09	X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise	MT

X4 Pharmaceuticals, Inc. Announces Resignation of Renato Skerlj as Chief Scientific Officer, Effective October 2, 2020

September 11, 2020 at 09:28 pm

X4 Pharmaceuticals, Inc. announced that Renato Skerlj has tendered his resignation as Chief Scientific Officer, effective at the close of business on October 2, 2020. Skerlj is leaving the Company to transition to become the President and CEO of a privately held biotechnology company.

Latest news about X4 Pharmaceuticals, Inc.

Sector Update: Health Care Stocks Higher Late Afternoon	05-09	MT
X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise	05-09	MT
X4 Pharmaceuticals, Inc. Draws an Additional Tranche of $20 Million Under Its Existing Loan Facility with Hercules Capital, Inc	05-09	CI
Transcript : X4 Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
X4 Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
HC Wainwright Adjusts Price Target on X4 Pharmaceuticals to $5 From $3, Maintains Buy Rating	04-30	MT
Pantherx® Rare Partner with X4 Pharmaceuticals Inc. for the Distribution of Xolremdi? (Mavorixafor), the First FDApproved Therapy Indicated for Use in Patients with Whim Syndrome	04-29	CI
X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome	04-29	MT
Transcript : X4 Pharmaceuticals, Inc. - Special Call	04-29
X4 Pharmaceuticals Gets FDA Approval for Xolremdi Capsules	04-29	DJ
X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome	04-29	CI
Transcript : X4 Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 21, 2024	03-21
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-21	CI
North American Morning Briefing : Investors -2-	03-21	DJ
North American Morning Briefing : Traders Await -2-	12-13	DJ
B. Riley Downgrades X4 Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $1 From $3	12-12	MT
X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023	12-09	CI
Transcript : X4 Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023	11-09
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
North American Morning Briefing : Traders Await -2-	11-09	DJ
X4 Pharmaceuticals Insider Sold Shares Worth $181,573, According to a Recent SEC Filing	11-03	MT
X4 Pharmaceuticals Insider Sold Shares Worth $168,371, According to a Recent SEC Filing	11-03	MT
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome	31/10/23	CI
X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors	18/10/23	CI
Transcript : X4 Pharmaceuticals, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 07:30 AM	13/09/23

Chart X4 Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Sector

Biotechnology & Medical Research

Calendar

10/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.01 USD

Average target price

4.117 USD

Spread / Average Target

+307.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
X4 PHARMACEUTICALS, INC.	+20.45%	170M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B

Bio Therapeutic Drugs